The Matricellular Receptor LRP1 Forms an Interface for Signaling and Endocytosis in Modulation of the Extracellular Tumor Environment

Bart Van Gool 1, Stéphane Dedieu 2, Hervé Emonard 2 and Anton J. M. Roebroek 1*

1 Laboratory for Experimental Mouse Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium, 2 Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7369 Matrice Extracellulaire et Dynamique Cellulaire, Université de Reims Champagne-Ardenne, Unité de Formation et de Recherche Sciences Exactes et Naturelles, Reims, France

INTRODUCTION

The matricellular receptor low-density lipoprotein receptor related-protein 1 (LRP1) has been attributed a role in cancer. However, its presumably often indirect involvement is far from understood. LRP1 has both endocytic and signaling activities. As a matricellular receptor it is involved in regulation, mostly by clearing, of various extracellular matrix degrading enzymes including matrix metalloproteinases, serine proteases, protease inhibitor complexes, and the endoglycosidase heparanase. Furthermore, by binding extracellular ligands including growth factors and subsequent intracellular interaction with scaffolding and adaptor proteins it is involved in regulation of various signaling cascades. LRP1 expression levels are often downregulated in cancer and some studies consider low LRP1 levels a poor prognostic factor. On the contrary, upregulation in brain cancers has been noted and clinical trials explore the use of LRP1 as cargo receptor to deliver cytotoxic agents. This mini-review focuses on LRP1’s role in tumor growth and metastasis especially by modulation of the extracellular tumor environment. In relation to this role its diagnostic, prognostic and therapeutic potential will be discussed.

Keywords: LRP1, cancer, extracellular matrix, metastasis, signaling, endocytosis
GENERAL ROLE OF LRP1 IN ENDOCYTOSIS AND CELL SIGNALING

Lipoprotein receptor related-protein 1, a type I transmembrane receptor, is a member of the LDL-receptor gene family (Lillis et al., 2008). The LRP1 precursor is cleaved by furin in the trans-Golgi to generate a 515 kDa N-terminal α-subunit and an 85 kDa C-terminal β-subunit. In the mature two-chain structure, the entirely extracellular α-subunit, containing the ligand binding domains, is non-covalently linked to the transmembrane-containing β-subunit. After maturation, arrival at the cell surface and ligand binding it undergoes highly efficient constitutive endocytosis via clathrin-coated pits and recycling. The dominant signals for endocytosis are YxxL and dileucine motifs in the cytoplasmic or intracellular domain of the β-subunit (Li et al., 2000), whereas two NPxY motifs, of which the latter overlaps with the YxxL motif, are secondary endocytosis signals and binding sites for adaptor proteins involved in signaling (Trommsdorff et al., 1998; Li et al., 2000; Loukinova et al., 2002). Analyses of knock-in mice and derived MEFs carrying inactivating mutations of the proximal NPxY and the distal NPxYxxL motifs revealed that, besides for endocytosis and signaling, these motifs are also relevant for slow recycling of LRP1 from the perinuclear compartment to the plasma membrane and even for early steps in LRP1 biosynthesis, preventing premature proteasomal degradation of precursor LRP1 (Roebroek et al., 2006; Gordts et al., 2009, 2012; Reekmans et al., 2010).

Lipoprotein receptor related-protein 1 ligands include proteases, protease inhibitor complexes, extracellular matrix proteins, growth factors, toxins, and viral proteins (Lillis et al., 2008). Via clearing of proteases, like (matrix)-metalloproteinases and other secreted proteins, like coagulation FVIII, LRP1 contributes to the homeostasis of many secreted proteins and the integrity of the extracellular matrix (Figure 1A). LRP1 regulates, however, also the abundance of many other proteins, including receptors present at the plasma membrane. For example, the urokinase-type plasminogen activator (uPA)-plasminogen activator inhibitor-1 (PAI-1) complex is a bivalent ligand, which triggers urokinase receptor (uPAR) internalization and regulates the uPAR signaling by bridging extracellularly uPAR and LRP1 (Gonias et al., 2011). Fe65 and PSD-95 are intracellular adaptor proteins (Figure 1B) that interconnect LRP1 to β-amyloid precursor protein (β-APP) (Pietrzik et al., 2004) and N-methyl-d-aspartate (NMDA) receptor (May et al., 2004; Martin et al., 2008) respectively, stimulating APP endocytosis and amyloid (Aβ) generation (Pietrzik et al., 2004), and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling (Martin et al., 2008).

LRP1 AND CANCER: A LONG BUT DIFFICULT MARRIAGE

Lipoprotein receptor related-protein 1 has already been attributed a role in cancer shortly after its discovery in 1988 (Herz et al., 1988). Initially, several groups reported decreased LRP1 expression (Figure 1C) levels in various cancer cell lines and tissues, thus assigning a tumor suppressive role to this receptor (Kancha et al., 1994; de Vries et al., 1996; Gilardoni et al., 2003). These findings provided a rationale for earlier studies in which decreased binding and uptake of α2-macroglobulin (α2M), an LRP1 ligand, were observed in multiple cancer cell lines (Van Leuven et al., 1979; Saksela et al., 1981, 1984; Jensen et al., 1989). It should be noted, however, that under normoxia cell culture conditions cancer cell lines in vitro might show a reduction in LRP1 expression compared to hypoxic conditions (Montel et al., 2007). As in many tumors in vivo hypoxic conditions exist, this observed decrease in LRP1 expression should be interpreted with caution. Nonetheless, more recent work supports a reduction in LRP1 expression in cancer. Amos et al. (2007) compared LRP1 expression between low-grade astrocytoma and high-grade astrocytoma (glioblastoma). They correlated a decrease in LRP1 expression with more advanced tumor grade and enhanced uPA-dependent cell invasion. Previously however, Yamamoto et al. (1997) and Baum et al. (1998) have described opposite results: LRP1 expression was predominantly detected in glioblastoma and to a lesser extent in lower grade astrocytomas. In vitro, LRP1 expression appears to vary substantially among different glioblastoma cell lines (Maletinska et al., 2000). In hepatocellular carcinoma, colorectal carcinoma and lung adenocarcinoma, reduced LRP1 expression levels were linked to a poor prognosis and more advanced tumor stages (Obermeyer et al., 2007; Meng et al., 2011; Huang et al., 2012). Recently, it was shown that LRP1 acts in response to ApoE as an endogenous suppressor of the metastatic phenotype in melanoma (Pencheva et al., 2012). However, contrasting evidence exists suggesting a role for LRP1 in supporting thyroid and breast cancer cell invasion and metastasis (Chazaud et al., 2002; Montel et al., 2007; Dedieu et al., 2008; Fayard et al., 2009). Moreover, increased LRP1 expression was found to be predictive of more aggressive tumor behavior and associated with higher histological grade in endometrial carcinomas (Catasus et al., 2011).

Post-translational regulation of LRP1 by proteolytic cleavage (also named shedding) is a critical mechanism in regulating cell-surface LRP1 expression, especially in tumor context (Figure 1D). Since the first identification of the extracellular part of LRP1 (LRP1-EC) solubilized in human plasma (Quinn et al., 1997), proteolytic enzymes from different classes have been identified as LRP1 sheddases (Etique et al., 2013). These include metalloproteinases such as MT1-MMP and ADAM-10 and -12, the serine proteinase tPA and BACE-1. Shedding of LRP1-EC allows the release from the plasma membrane by γ-secretase of the intra-cytoplasmic domain of LRP1 (LRP1-IC), which could act as signaling mediator (May et al., 2002). Accumulation of extracellular proteolytic activities associated to the tumor microenvironment could explain at least in part why cell-surface LRP1 is generally found decreased in advanced tumors. However, the significance of LRP1 shedding is not really understood in the field of malignant diseases.

Only a few LRP1 polymorphisms or mutations were identified in cancer specimens. Benes et al. (2003) associated the C766T polymorphism with an increased risk to develop breast cancer in Caucasian women. Although this change into a thymine nucleotide does not result in an amino acid substitution, this silent mutation has previously also been linked to Alzheimer's
Modulation of cancer by LRP1

FIGURE 1 | Schematic representation of LRP1-mediated tumor growth and metastasis fine tuning. (A) LRP1 clears various cancer-related ligands from the ECM by endocytosis. (B) The LRP1 ICD also interacts with several adaptor and scaffolding proteins. (C) LRP1 expression levels vary among different tumor types and tumor stages and (D) the receptor can undergo shedding and subsequent release of the ICD. (E) Heparanase-1 activation is affected by LRP1-mediated uptake of its inactive precursor. (F) The formation of co-receptor complexes with LRP1 influences signaling and also the phosphorylation of the LRP1 ICD influences signaling and regulates endocytosis. (H) LRP1-mediated signaling affects several well-known pathways linked to cancer.

A MULTITUDE OF CANCER-MODIFYING PATHWAYS

Remodeling of the ECM is essential for both tumor growth and metastasis. As a matricellular receptor, LRP1 is involved in the regulation of several ECM modifying pathways.

(Matrix)-metalloproteinases (MMPs) are key enzymes in physiological but also in cancer-related modulation of ECM and basement membrane components. Their proteolytic function mostly results in inactivation or degradation of many of their different substrates. MMPs are, however, also found involved in signaling functions in a non-proteolytic manner.
LRP1 mediates endocytosis of MMP-2, -9, -13, ADAMTS-4 and ADAMTS-5 and clears these proteases from the ECM (Emonard et al., 2005; Yamamoto et al., 2014, 2015). Endocytosis by LRP1 can depend on complex formation: (pro)MMP-2:TSP-2 (thrombospondin-2), proMMP-2:TIMP-2 (tissue inhibitor of metalloproteinases 2), and proMMP-9:TIMP-1 complexes are all ligands to LRP1 and cleared by this receptor (Emonard et al., 2005; Yamamoto et al., 2015). Furthermore, other MMPs are being regulated by LRP1, although indirectly, via the clearance of TIMP-1, -2, and -3 by LRP1 whether bound to an MMP (Emonard et al., 2005; Yamamoto et al., 2015) or alone (TIMP-1 and -3; Sciabarra et al., 2013; Thevenard et al., 2014). These TIMPs also display signaling functions via the ERK and Wnt pathways (Liu et al., 2003; Egea et al., 2012). Also the broad spectrum protease inhibitor α2(M binds to LR1P1 followed by subsequent internalization (Andersen et al., 2000). Not only metalloproteinases are a target of this glycoprotein but also serine-, carboxyl-, and thiol proteinases are blocked from interacting with their respective substrates (Rehman et al., 2013). Besides its activity as a protease inhibitor, α2(M was recently shown to stimulate angiogenesis via activation of stem cells through FGF-2 and nitric oxide via LRP1-mediated signaling (Sauer et al., 2013).

Heparanase-1 is another matrix modifying enzyme that is endocytosed by LR1P1, both for its activation and clearance (Figure 1E). This enzyme cleaves heparan sulfate proteoglycans (HSPG), one of the core components of the ECM (Ilan et al., 2006). HSPGs not only play a role in the integrity of the ECM but also act as a storage depot for growth factors, chemokines, cytokines and enzymes. Heparanase-1 is synthesized as an inactive precursor. Activation requires proteolytic cleavage that is partly dependent on LR1P1-mediated pro-heparanase-1 internalization (Figure 1E; Vreys et al., 2005). Also mature heparanase-1 can be endocytosed by LR1P1 targeting it for degradation or recycling (Vreys and David, 2007).

uPA-uPAR signaling is another migration- and invasion-related pathway regulated by LR1P1 that can promote cell invasion and migration (Webb et al., 2000; Amos et al., 2007; Gonias et al., 2011). uPA and tPA proteinase activity are implicated in the plasminogen activator system and as such mediate plasmin-dependent degradation of ECM proteins (Gonias et al., 2011). Interaction of uPA with PAl-1 on uPAR stimulates uPAR-LRP1 complex formation and subsequent endocytosis (Czekay et al., 2001). This affects uPAR presence at the plasma membrane with consequences for ECM degradation via the plasminogen activation system and uPAR-integrin interaction, both important for cell migration. Also for angiogenesis the uPA-plasmin system is highly relevant (Raghu et al., 2010). Furthermore, LR1P1 was shown to promote maturation of the integrin β1 precursor thereby increasing the level of integrin β1 at the cell surface (Salicioni et al., 2004). LR1P1 also binds to α5β1, thereby altering integrin function. In macrophages, LR1P1 is important for α5β1 internalization thereby possibly influencing macrophage-mediated inflammation (Ranganathan et al., 2011).

Migration of malignant cells is further affected by LR1P1-CD44 complexes in the cell membrane (Figure 1F). LR1P1 was recently shown to control the adhesion in tumor cells via interaction with, and internalization of CD44, a transmembrane glycoprotein (Perrot et al., 2012). CD44 mediates cell adhesion to the ECM, migration and is probably involved in tumor and metastasis initiation. Like LR1P1, CD44 acts as an interface for signal transduction at the cell surface as recently reviewed (Orian-Rousseau, 2015). A lowering in LR1P1 expression as observed in certain cancers (see supra) could thus result in CD44 accumulation at the cell surface and enforced cancer cell attachment.

Besides this, probably far from complete, overview of LR1P1-related ECM modifying processes, LR1P1 also forms co-receptor complexes (Figure 1F) at the cell surface with receptors involved in cancer-related pathways. A good example is the association between LR1P1 and the platelet-derived growth factor receptor-β (PDGFR-β). LR1P1 not only mediates PDGFR internalization and degradation, in two accompanying papers, PDGFR-BB was shown to mediate the phosphorylation (Figure 1G) of the Tyr63 in the distal NPXY motif of LR1P1 located in caveolae (Boucher et al., 2002; Loukina et al., 2002). This process is dependent on PDGFR activation and on the kinase activity of the c-Src family of proto-oncogenic tyrosine kinases. This relationship links LR1P1 to Ras, c-Myc, MAPK, and Akt/PI3K signaling, well known pathways implicated in oncogenesis (Figure 1H). Later, LR1P1 was shown to directly associate with PDGFR-β to form a signal transduction complex (Newton et al., 2005; Muratoglu et al., 2010). As such PDGFR signaling is influenced by LR1P1 and vice versa. Recently, the group of May demonstrated that LR1P1’s ICD also modulates the crosstalk between PDGFR-BB and sphingosine-1 which is important for modulation of PDGFR-BB induced cell migration and blood vessel maturation (Nakajima et al., 2014). The possible dependence for tumor angiogenesis is yet to be determined. LR1P1 also affects angiogenesis among other things via its regulatory role in VEGF signaling. The complex of the angiogenic inhibitor thrombospondin-1 and VEGF is internalized via LR1P1 (Greenaway et al., 2007).

**THE RELEVANCE OF LR1P1 FOR THE INTERACTION BETWEEN MALIGNANT CELLS AND THE TUMOR (MICRO)ENVIRONMENT**

Both LR1P1 expressed in malignant cells themselves and LR1P1 expressed in non-tumorous cells present in the tumor (micro)environment are relevant for modulation of the above described cancer-modifying pathways. These pathways are involved in processes like growth and survival of tumor cells, angiogenesis, extravasation of tumor cells, invasion and metastasis. The relative expression of LR1P1, its ligands and co-receptors, irrespective whether expressed by the tumor cells themselves or other cells in the tumor (micro)environment determine the modifying role of LR1P1 in these different, but linked processes, which may in fact result in opposing effects on cancer progression.

Montel et al. (2007) silenced LR1P1 in tumor cells only and host LR1P1 was left untouched. They observed the failure of metastatic
foci to grow in the lungs from xenografts of CL16 cells in SCID mice thus illustrating the relevance of LRPI expression in tumor cells themselves.

Also the importance of LRPI expression in non-tumor cells in the tumor environment has been demonstrated. In the breast tumor microenvironment, it was reported that the pro-cath-D protease, highly secreted by tumor cells, may trigger mammary fibroblast outgrowth in a paracrine LRPI-dependent manner (Beaujouin et al., 2010). The molecular mechanism engaged appears atypical as pro-cath-D interacts with the extracellular part of LRPI β-subunit mediating the inhibition of LRPI-regulated intramembrane proteolysis in mammary fibroblasts (Deroq et al., 2012; Laurent-Matha et al., 2012). Recently, Staudt et al. (2013) demonstrated that the recruitment of LRPI-deficient monocytes into subcutaneous and orthotopic pancreatic tumors were significantly increased. The secretion of chemokines by LRPI-deficient macrophages is enhanced (especially CCL3), resulting in an increased number of tumor-associated macrophages (TAM) in the tumor site. The authors provided evidence that the LRPI-deficient TAM collectively contribute to an increased VEGF amount into the tumor microenvironment, leading to increased tumor angiogenesis.

The aforementioned role of LRPI in heparanase activation and uptake implicates a potential regulatory role for LRPI in exosomes biogenesis. As reviewed elsewhere (De Toro et al., 2015), exosomes are nanovesicles secreted by various cell types, including cancer cells, that serve in cell–cell communication. They can be isolated from body fluids and are regarded potential biomarkers for diagnosis and prognosis. As recently shown, syndecan heparan sulfate (HS) proteoglycans and heparanase are involved in exosome production (Baietti et al., 2012; Roucourt et al., 2015). Trimming of HS chains on syndecan molecules by heparanase appears to affect the formation of multimeric complexes of syndecans, co-receptors and the intracellular adaptor protein syntenin triggering the generation of intraluminal vesicles in multivesicular bodies (MVBs), eventually resulting in the release of exosomes. Heparanase apparently does not only regulate secretion of tumor-cell derived exosomes, but also its composition and function (Thompson et al., 2013). As such, LRPI-mediated control on active heparanase availability could effect exosome production and function.

**DRUG DELIVERY ACROSS THE BLOOD–BRAIN BARRIER**

Current studies on therapeutic strategies involving LRPI focus on using it as a cargo receptor to treat brain metastases. The aforementioned expression of LRPI in glioblastoma and other brain cancers (Yamamoto et al., 1997; Baum et al., 1998) or metastasis combined with LRPI’s expression at the BBB (Pilanzner et al., 2011) is crucial to this strategy. The capability of LRPI to mediate transcytosis of a broad range of ligands through the BBB (Figure 2A) could be the long-awaited sluice for chemotherapeutic agents into the brain as BBB penetration is currently the Achilles’ heel in brain cancer therapies (Jovčevska et al., 2013). Uptake of paclitaxel through the BBB followed by endocytosis into tumor cells was shown to be increased after conjugating the taxane paclitaxel to a 19 amino acid sequence named angiopep-2 (Bertrand et al., 2011). This peptide was derived from the Kunitz domain, a known ligand of LRPI. A phase I clinical study showed that this conjugate (GRN1005) is well tolerated (Kurzrock et al., 2012; Drappatz et al., 2013). Therapeutic concentrations could be reached in the tumor and three patients where prior taxane therapy was unsuccessful showed partial response with GRN1005. After an initial phase II study, additional phase II studies are currently ongoing for patients with brain metastases from breast cancer and high grade glioma. Also other constructs are evaluated preclinically including an anti-HER2 antibody conjugated to angiopep-2 to treat brain metastasis from HER2 positive breast cancers (Regina et al., 2015). As demonstrated recently in vitro and in animal studies, angiopep-2 could also aid active transport of polymersomes through the BBB via LRPI mediated transcytosis suitable for antibody delivery to the brain (Tian et al., 2015). Apart from angiopep-2, also peptides containing a serine-arginine-leucine (SRL) sequence bind LRPI and were recently...
shown to aid PAMAM nanoparticle transport across the BBB (Zarebkoohan et al., 2015). These LRP1 targeted particles could become a valuable tool for non-invasive gene targeting to the brain.

Although highly challenging, developing strategies aiming at LRP1 targeting should be relevant in certain tumor microenvironments. We might consider new LRP1 antagonists targeting the extracellular part of the LRP1 β-subunit to avoid LRP1 itself being internalized and catabolized (Figure 2B). Another alternative could be to use the soluble LRP1-ECD as a decoy receptor to interfere with endocytic and signaling activities of cell-surface LRP1 (Figure 2C). The proof of concept exists for TIMP-3. Bound to LRP1-ECD, TIMP-3 becomes resistant to endocytosis and degradation and retains its inhibitory activity against metalloproteinases (Scilabra et al., 2013). LRP1 ligand-binding domains II and IV are probably the most critical regions that could serve as molecular and structural models for designing new therapeutic tools.

**POTENTIAL OF LRP1 IN DIAGNOSIS AND PROGNOSIS**

As discussed previously, in some cancer types, LRP1 expression was correlated with invasiveness, tumor stage, and even clinical outcome. However, although it has been suggested that LRP1 could be a potential biomarker (Meng et al., 2011), so far, there seems to be lots of variability and discussion. As mentioned before, LRP1 expression in cell cultures is also debatable as the in vitro conditions could affect LRP1 expression. Recent work on data from tumor samples identified LRP1 as a hub in a biomarker network for multi-cancer clinical outcome prediction (Martinez-Ledesma et al., 2015). This further illustrates the involvement and possible prognostic value of LRP1 in various cancers. Future large scale studies on patient samples could provide more insights and demonstrate the true relevance of LRP1 in diagnosis and prognosis of cancer.

**CONCLUSION**

Via a diverse array of interactions LRP1 modules various pathways involved in cancer. Especially its role in modifying the ECM could be crucial for tumor growth and metastasis. However, considering the sometimes contradicting studies LRP1 cannot be considered a master switch as some prototype oncogenes or tumor suppressor genes are. Rather, it acts as an interface to fine-tune various cancer-related pathways. Its effects appear to be dependent on both the tumor type and the tumor environment. This complicates LRP1 research and calls for good model systems that integrate the diverse set of LRP1 activities. These should answer the question whether LRP1 could be a valuable target for diagnosis, prognosis and therapeutics in cancer as well as other diseases.

**ACKNOWLEDGMENTS**

This work was supported by a post-graduate grant of the Agency for Innovation by Science and Technology (IWT) to BVG, by grants of the Fund for Scientific Research-Flanders (FWO, G.0529.08N) and the Concerted Actions Program of the KU Leuven (GOA/12/016) to AR. SD and HE acknowledge supports from CNRS and Ligue Nationale Contre le Cancer (CCIR-GE, Conférence de Coordination InterRégionale du Grand Est).

**REFERENCES**

Amos, S., Mut, M., diPierro, C. G., Carpenter, J. E., Xiao, A., Kohutek, Z. A., et al. (2007). Protein kinase C-α-mediated regulation of low-density lipoprotein receptor related protein and urokinase increases astrocytoma invasion. Cancer Res. 67, 10241–10251. doi: 10.1158/0008-5472.CAN-07-0030

Andersen, O. M., Christensen, P. A., Christensen, L. L., Jacobsen, C., Moestrup, S., et al. (2010). Pro-cathepsin D interacts with the extracellular domain of the lipoprotein receptor related protein gene amplification and 766T polymorphism and susceptibility to breast cancer. Breast Cancer Res. 12, 3202–3212. doi: 10.1186/bcr2980–2995. doi: 10.1128/MCB.02238-07

Cekay, R. P., Kuemmel, T. A., Orlando, R. A., and Farquhar, M. G. (2001). Direct binding of occupied urokinase receptor (υPAR) to LDL receptor-related protein is required for endocytosis of υPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell 12, 1467–1479. doi: 10.1091/mbc.12.5.1467

Czekay, R. P., Kuemmel, T. A., Orlando, R. A., and Farquhar, M. G. (2001). Direct binding of occupied urokinase receptor (υPAR) to LDL receptor-related protein is required for endocytosis of υPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell 12, 1467–1479. doi: 10.1091/mbc.12.5.1467

Derocq, D., Prebois, C., Beaujouin, M., Laurent-Matha, V., Pattingre, S., Smith, G. Derocq, D., Prebois, C., Beaujouin, M., Laurent-Matha, V., Pattingre, S., Smith, G. et al. (2008). Chazaud, B., Ricoux, C., Christov, C., Plonquet, A., Gherardi, K., and Barlovatz-Meimon, O. (2002). Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am. J. Pathol. 160, 237–246. doi: 10.1016/S0002-9440(10)64367-2

De Toro, J., Herschlik, L., Waldner, C., and Mongini, C. (2015). Emerging roles of LRP1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities. Mol. Cell. Biol. 28, 2980–2995. doi: 10.1128/MCB.02238-07

Dedieu, S., Langlois, B., Devy, J., Sid, B., Henriet, P., Sartelet, H., et al. (2008). Confronting tumor invasion with the LRP1 receptor. Cancer Res. 68, 6776–6784. doi: 10.1158/0008-5472.CAN-08-0731

Moulaert, F., Janssens, J., van de Vrie, R., de Vries, T. J., Verheijen, J. H., de Bart, A. C., Weidle, U. H., Ruiter, D. J., and van Muijen, G. N. (1996). Decreased expression of both the low-density lipoprotein receptor-related protein 1 and 2 is associated with highgrade, advanced stage and p53 and p16 alterations in endometrial carcinomas. Histopathology 59, 567–571. doi: 10.1111/j.1365-2559.2011.03942.x

Scilabra, T. J., Verheijen, J. H., de Bart, A. C., Weidle, U. H., Ruiter, D. J., and van Muijen, G. N. (1996). Decreased expression of both the low-density lipoprotein receptor-related protein 1 and 2 is associated with highgrade, advanced stage and p53 and p16 alterations in endometrial carcinomas. Histopathology 59, 567–571. doi: 10.1111/j.1365-2559.2011.03942.x
receptor-related protein/α2-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression. Cancer Res. 56, 1432–1439.

Drappatz, J., Breitner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., et al. (2013). Phase I study of GRN1005 in recurrent malignant glioma. Clin. Cancer Res. 19, 1567–1576. doi: 10.1158/0146-1580.CCR-12-2481

Egea, V., Zahir, S., Riet, N., Neth, P., Popp, T., Kehe, K., et al. (2012). Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling. Proc. Natl. Acad. Sci. U.S.A. 109, E309–E313. doi: 10.1073/pnas.1110830109

Emonard, H., Bellon, G., de Diesbach, P., Mettlin, M., Honebeckw, W., and Courtoy, P. J. (2005). Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein (LRP). A new function for an "old friend". Biochimie 87, 369–376. doi: 10.1016/j.biochi.2004.11.013

Etique, N., Verzeaux, L., Dedieu, S., and Emonard, H. (2013). LRP-1: a checkpoint regulators of the tumor microenvironment. Cell Biol. Physiol. 2013, 152163. doi: 10.1155/2013/152163

Fayard, B., Bianchi, F., Dey, J., Moreno, E., Djaffer, S., Hynes, N. E., et al. (2009). The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Res. 69, 5690–5698. doi: 10.1158/0008-5472.CAN-08-4573

Gilardoni, M. B., Ceschin, D. G., Sahores, M. M., Oviedo, M., Gehrau, R. C., and Forni, G. (2009). The low-density lipoprotein receptor-related protein 1 and amyloid-β-phosphate signaling and is essential for vascular development. Development 141, 4513–4525. doi: 10.1242/dev.091124

Kessenbrock, K., Wang, C. Y., and Werb, Z. (2015). Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol. 44–46, 184–190. doi: 10.1016/j.matbio.2015.01.022

Kolesch, H., Ptok, U., Mohandes, L., Schmitz, S., Rao, M. L., Maier, W., et al. (2003). Association of the 2767T polymorphism of the low-density lipoprotein receptor-related protein gene with Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 121B, 128–130. doi: 10.1002/ajmg.b.20043

Kurzrock, R., Gabrail, N., Chandhaisin, C., Moulder, S., Smith, C., Brenner, A., et al. (2012). Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopoiet-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol. Cancer Ther. 11, 308–316. doi: 10.1158/1535-7163.MCT-11-0566

Laurent-Matha, V., Huesgen, P. F., Masson, O., Derooq, D., Prebois, C., Garry-Bobo, M., et al. (2012). Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment. FASEB J. 26, 5172–5181. doi: 10.1096/fj.12-205229

Li, Y., Marzolo, M. P., van Kerkhof, P., Strous, G. J., and Bu, G. (2000). The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein. J. Biol. Chem. 275, 17187–17194. doi: 10.1074/jbc.M000490200

Lillis, A. P., Van Duyun, L. B., Murphy-Ullrich, J. E., and Strickland, D. K. (2008). LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 88, 887–918. doi: 10.1152/physrev.00033.2007

Liu, X. W., Bernardo, M. M., Fridman, R., and Kim, H. R. (2003). Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J. Biol. Chem. 278, 40364–40372. doi: 10.1074/jbc.M302999200

Lokunin, E., Ranganathan, S., Kuznetsov, S., Gorlatova, N., Migliorini, M. M., Lokunin, D., et al. (2002). Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function between LRP and the PDGF. J. Biol. Chem. 277, 25499–25506. doi: 10.1074/jbc.M200427200

Malteinska, L., Blakely, E. A., Bjornstad, K. A., Deen, D. F., Knoff, L. J., and Forte, T. M. (2000). Human globlinoma cell line cells: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res. 60, 2300–2303.

Martin, A. M., Kuhlmann, C., Trossbach, S., Jaeger, S., Waldron, E., Roebroek, A., et al. (2008). The functional role of the second NPXY motif of the LRP1 β-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. J. Biol. Chem. 283, 2300–2303. doi: 10.1074/jbc.M201979200

May, P., Reddy, Y. K., and Herz, J. (2002). Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J. Biol. Chem. 277, 18736–18743. doi: 10.1074/jbc.M201979200

May, P., Rohmlh, A., Bock, H. H., Zsurho, K., Marsh, J. D., Schomburg, E. D., et al. (2004). Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol. Cell. Biol. 24, 8872–8883. doi: 10.1128/MCB.24.20.8872-8883.2004

Meng, H., Chen, G., Zhang, X., Wang, Z., Thomas, D. G., Giordano, T. J., et al. (2011). Stromal LRP1 in lung adenocarcinoma predicts clinical outcome. Clin. Cancer Res. 17, 2426–2433. doi: 10.1158/1078-0432.CCR-10-2385

Montel, V., Gaultier, A., Lester, R. D., Campana, W. M., and Gonias, S. L. (2007). The low-density lipoprotein receptor-related protein regulates cancer cell survival and metastasis development. Cancer Res. 67, 9817–9824. doi: 10.1158/0008-5472.CAN-07-0683

Muratoğlu, S. C., Mikkalinen, I., Newton, C., Migliorini, M., and Strickland, D. K. (2010). Low density lipoprotein receptor-related protein 1 (LRP1) forms a signaling complex with platelet-derived growth factor receptor-β in endosomes and regulates activation of the MAPK pathway. J. Biol. Chem. 285, 14308–14317. doi: 10.1074/jbc.M109.046672

Nakajima, C., Haffiner, P., Goerke, S. M., Zuroh, K., Adelmann, G., Frotscher, M., et al. (2014). The lipidprotein receptor LRP1 modulates sphingosine-1-phosphate signaling and is essential for vascular development. Development 141, 4513–4525. doi: 10.1242/dev.091124
Newton, C. S., Loukinova, E., Mikhailenko, I., Ranganathan, S., Gao, Y., Haudenschild, C., et al. (2005). Platelet-derived growth factor receptor-β (PDGFBR-β) activation promotes its association with the low density lipoprotein receptor-related protein (LRP). Evidence for co-receptor function. J. Biol. Chem. 280, 27782–27787. doi: 10.1074/jbc.M505410200

Obermeyer, K., Krueger, S., Peters, B., Falkenberg, B., Roessner, A., and Rocken, C. (2007). The expression of low density lipoprotein receptor-related protein in colorectal carcinoma. Oncol. Rep. 17, 361–367. doi: 10.3892/or.17.2.361

Orian-Rousseau, V. (2015). CD44 acts as a signaling platform controlling tumor progression and metastasis. Front. Immunol. 6:154. doi: 10.3389/fimmu.2015.00154

Pencheva, N., Tran, H., Buss, C., Huh, D., Drobnjak, M., Busam, K., et al. (2012). Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell 151, 1068–1082. doi: 10.1016/j.cell.2012.10.028

Perrot, G., Langlois, B., Devy, J., Jeanne, A., Verzeaux, L., Almagro, S., et al. (2012). LRP-1-CD44, a new cell surface complex regulating tumor cell adhesion. Mol. Cell. Biol. 32, 3293–3307. doi: 10.1128/MCB.00228-12

Pflanzner, T., Janko, M. C., Andre-Dohmen, B., Reuss, S., Weggen, S., Roebroek, A. J., et al. (2011). LRP1 mediates bidirectional transcytosis of amyloid-β across the blood–brain barrier. Neurobiol. Aging 32, 2323.e1–2323.e11. doi: 10.1016/j.neurolaging.2010.05.025

Pietrzik, C. U., Yoon, I. S., Jaeger, S., Busse, T., Weggen, S., and Koo, E. H. (2005). Interaction of the intracellular domain of LRP1 for normal fetal development. Mol. Cell. Biol. 25, 115–121. doi: 10.1128/MCB.00228-12

Quinn, K. A., Grinsley, P. G., Tai, Y. P., Tapner, M., Chesterman, C. N., and Owensby, D. A. (1997). Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J. Biol. Chem. 272, 23946–23951. doi: 10.1074/jbc.272.38.23946

Raghuram, H., Lakka, S. S., Gondi, C. S., Mohanam, S., Dinh, D. H., Gujrati, M., et al. (2010). Suppression of upa and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS ONE 5:e12458. doi: 10.1371/journal.pone.0012458

Ranganathan, S., Cao, C., Catania, J., Migliorini, M., Zhang, L., and Strickland, D. D. (2011). Molecular basis for the interaction of LRP1 in the interaction of LRP1 with integrin receptor related protein 1 (LRP1) with integrin αβ3/β6: identification of binding sites within αβ3β6 for LRP1. J. Biol. Chem. 286, 30535–30541. doi: 10.1074/jbc.M111.265413

Reekmans, S. M., Pflanzner, T., Gords, P. L., Isbert, S., Zimmermann, P., Annaert, W., et al. (2010). Inactivation of the proximal NPXY motif impairs early steps in LRP1 biosynthesis. Cell. Mol. Life Sci. 67, 135–145. doi: 10.1007/s00018-009-0717-1

Regina, A., Deumele, M., Tripathy, S., Lord-Dufour, S., Currie, J. C., Iddir, M., et al. (2015). ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol. Cancer Ther. 14, 129–140. doi: 10.1158/1535-7163.MCT-14-0399

Rehm, A. A., Ahlsan, H., and Khan, F. H. (2013). α2-Macroglobulin: a physiological guardian. J. Cell. Physiol. 228, 1665–1675. doi: 10.1002/jcp.24266

Roebroek, A. J., Reekmans, S., Lauwers, A., Feyaerts, N., Smeijers, L., and Hartmann, D. (2006). Mutant Lrp1 knock-in mice generated by recombinase-mediated cassette exchange reveal differential importance of the NPXY motifs in the intracellular domain of LRP1 for normal fetal development. Mol. Cell. Biol. 26, 605–616. doi: 10.1128/MCB.26.605-616.2006

Roucourt, B., Meussen, S., Bao, J., Zimmermann, P., and David, G. (2015). Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Res. 25, 412–428. doi: 10.1038/cr.2015.29

Saksela, O., Wahlstrom, T., Lehtovirta, P., Seppala, M., and Valheri, A. (1981). Presence of α2-macroglobulin in normal but not in malignant human syncytiotrophoblasts. Cancer Res. 41, 2507–2513.
protein/a2-macroglobulin receptor in human malignant astrocytomas. Cancer Res. 57, 2799–2805.
Yang, J., Annala, M., Ji, P., Wang, G., Zheng, H., Codgell, D., et al. (2014). Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma. J. Hematol. Oncol. 7, 76. doi: 10.1186/s13045-014-0076-2
Zarebkohan, A., Najafi, F., Moghimi, H. R., Hemmati, M., Deevband, M. R., and Kazemi, B. (2015). Synthesis and characterization of a PAMAM dendrimer nanocarrier functionalized by SRL peptide for targeted gene delivery to the brain. Eur. J. Pharm. Sci. 78, 19–30. doi: 10.1016/j.ejps.2015.06.024

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Van Gool, Dedieu, Emonard and Roebroek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.